Apoptosis pathways in neuroblastoma therapy

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 131-135

  Fulda, Simone ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

APO 1; Apoptosis; Caspases; CD95; Chemoresistance; Chemotherapy; Cytotoxic; Death receptors; Drug response; FAS; Mitochondria; Neuroblastoma; p53; Targeting; Therapy; TRAIL

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; CASPASE 9; CASPASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; LIVIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL SURVIVAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DNA CLEAVAGE; DRUG MECHANISM; ENZYME ACTIVITY; GENE TARGETING; HUMAN; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0038444707     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00091-0     Document Type: Conference Paper

References (14)

1. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17:1999;2264-2279.
2. Fulda S., Debatin K.M. Caspase activation in cancer therapy. Los M., Walczak H. Caspases - Their Role in Cell Death and Cell Survival. 2002;Kluwer Academic Press.
3. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-777.
4. Thornberry N., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
5. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer. 2:2002;277-288.
6. Van Loo G., Saelens X., Van Gurp M., MacFarlane M., Martin S.J., Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 9:2002;1031-1042.
7. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A., Behm F.G., Look A.T., Lahti J.M., Kidd V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6:2000;529-535.
8. Fulda S., Kufer M.U., Meyer E., van Valen F., Dockhorn-Dworniczak B., Debatin K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 20:2001;5865-5877.
9. Altieri D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7:2001;542-547.
10. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:2002;808-815.
11. Antonsson B., Martinou J.C. The Bcl-2 protein family. Exp. Cell Res. 256:2000;50-57.
12. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
13. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
14. Reynolds C.P. Ras and Seppuku in neuroblastoma. J. Natl. Cancer Inst. 94:2002;319-321.